Celadon Pharmaceuticals Regulatory News (CEL)

28 Mar 2007 07:01

Celsis International PLC28 March 2007 CELSIS INTERNATIONAL PLC ("Celsis" or "the Company") PRE-CLOSE TRADING UPDATE 28 March 2007: Celsis International plc, the life sciences products andlaboratory services company, today announces an update on trading prior to thecommencement of its close period for the year ending 31 March 2007. The Company has made excellent progress during the year, including thecompletion of the acquisition of In Vitro Technologies Inc ("IVT"). Celsis IVTcontinues to perform to plan, with the integration progressing well. Celsis IVTis a leading worldwide supplier of in vitro products designed to help reduce thetime and cost of drug discovery and development and the Company foreseesexcellent future growth from this new division. The Analytical Services division has experienced particularly strong growthduring the second half of the year, building on its outstanding first half. TheCompany expects this division to maintain its strong performance in the nextfinancial year. As part of the IVT integration, the Analytical Servicesdivision has expanded its services offering to include IVT's DevelopmentServices. The Rapid Detection division has recovered from its first half year performance. Instrument placements into all sectors have improved and reagent kit ordershave been particularly strong following a realignment of the division'sscientific support resources with improved metrics on system implementations andcustomer response times. As a result, with all the divisions performing well, the Company is on track toannounce strong overall revenue growth and profits for the year ended 31 March2007. Celsis also announces today that it is appointing Numis Securities Ltd as theCompany's financial adviser and stockbroker with immediate effect. Celsis will announce its preliminary results for the year ended 31 March 2007,on Tuesday 19 June 2007. There will be a presentation to analysts on the day at9.30am, held at Financial Dynamics, Holborn Gate, 26 Southampton Buildings,London, WC2A 1PB. Jay LeCoque, Chief Executive Officer of Celsis, commented: "I am pleased to report that Celsis expects to announce another strong set ofyear end results. The three Celsis business divisions are performing well andwe have substantial growth synergies available to us from Celsis IVT. I remainenthusiastic about the Company's prospects as we continue our strategy ofproviding innovative products and services which benefit our customers by savingthem time and money. "I am also encouraged to announce the Company's appointment of Numis as Celsis'stockbroker and financial advisor. We very much look forward to working withNumis, who have great expertise in the life science sector, and being supportedby them as Celsis continues its continued growth and future development." Enquiries: Celsis International plc Tel: 01638 600 153Jay LeCoque, Chief Executive OfficerJenny Parsons, Corporate Communications Numis Securities Ltd Tel: 020 7260 1000Michael MeadeJames Black Financial Dynamics Tel: 020 7831 3113Anna KeebleBen Atwell Notes to editors Celsis International plc Celsis International plc provides value enhancing products and services to thepharmaceutical, biopharmaceutical, and consumer products industries through itsthree business areas; rapid detection, analytical services and in vitrotechnologies. The company is listed on the London Stock Exchange (CEL.L). Each division of Celsis has the capacity to deliver substantial time and costsavings to its customers, in addition to ensuring product quality and safety forconsumers. Using proprietary technology, the rapid detection business is theworld leader in the provision of diagnostic systems for the rapid detection ofcontamination. By reducing the time it takes to test and release raw materialsand finished goods to the market place, Celsis technology facilitates increasedmanufacturing productivity and improved supply chain management. The analyticalservices division provides outsourced laboratory testing services topharmaceutical and biopharmaceutical companies to ensure the stability andchemical composition of their products. In Vitro Technologies (IVT) supplies invitro testing products and services to the pharmaceutical and biotechnologyindustries. IVT's in vitro products and services screen drug compounds early inthe discovery process, thereby reducing the time and cost of drug development. Further information can be found on its website at www.celsis.com. This information is provided by RNS The company news service from the London Stock Exchange